TEE
PBYI icon

Tibra Equities Europe’s Puma Biotechnology PBYI Stock Holding History

Tibra Equities Europe’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-43,500
Closed -$553K – 304
2019
Q2 		$553K Buy
+43,500
New +$1M 0.04% 187
2019
Q1 		– Sell
-15,200
Closed -$309K – 450
2018
Q4 		$309K Buy
+15,200
New +$456K 0.05% 158

Other funds holding PBYI

PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Tibra Equities Europe's PBYI Position: Q3 2019 in Review

Tibra Equities Europe sold out of Puma Biotechnology (PBYI) in Q3 2019, closing a stake of 43,500 shares — an estimated $553K sold.

Tibra Equities Europe first reported a position in PBYI in Q4 2018 and held it in 2 quarters. The position peaked at $553K in Q2 2019. 144 funds tracked by Wall St. Rank hold PBYI as of Q3 2019.

  • Tibra Equities Europe reported no remaining Puma Biotechnology position as of Q3 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 43,500 Puma Biotechnology shares in Q3 2019, an estimated $553K.
  • Tibra Equities Europe first reported a position in Puma Biotechnology in Q4 2018 and held it in 2 quarters.
  • Tibra Equities Europe's Puma Biotechnology position peaked at $553K in Q2 2019.
  • 144 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2019.

Based on Tibra Equities Europe's 13F filing for Q3 2019, filed 4 Nov 2019.